These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 15749678

  • 1. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia.
    Cortelezzi A, Pasquini MC, Sarina B, Bertani G, Grifoni F, Colombi M, Lambertenghi Deliliers G.
    Haematologica; 2005 Mar; 90(3):410-2. PubMed ID: 15749678
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H, German Chronic Lymphocytic Leukemia Study Group.
    J Clin Oncol; 2009 Aug 20; 27(24):3994-4001. PubMed ID: 19597025
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
    Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R, Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia.
    Cancer; 2006 Nov 15; 107(10):2408-16. PubMed ID: 17054106
    [Abstract] [Full Text] [Related]

  • 5. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E.
    J Clin Oncol; 2006 May 20; 24(15):2337-42. PubMed ID: 16618945
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
    Cortelezzi A, Pasquini MC, Gardellini A, Gianelli U, Bossi A, Reda G, Sarina B, Musto P, Barcellini W, Neri A, Deliliers GL.
    Leukemia; 2009 Nov 20; 23(11):2027-33. PubMed ID: 19641526
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA.
    Cancer; 2008 Mar 15; 112(6):1288-95. PubMed ID: 18189296
    [Abstract] [Full Text] [Related]

  • 9. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
    Laurenti L, Piccioni P, Tarnani M, Efremov DG, Fiorini A, Garzia M, Sica S.
    Haematologica; 2005 Aug 15; 90(8):1143-5. PubMed ID: 16079121
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
    Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L.
    J Clin Oncol; 2002 Sep 15; 20(18):3891-7. PubMed ID: 12228210
    [Abstract] [Full Text] [Related]

  • 13. The evolving role of alemtuzumab in management of patients with CLL.
    Faderl S, Coutré S, Byrd JC, Dearden C, Denes A, Dyer MJ, Gregory SA, Gribben JG, Hillmen P, Keating M, Rosen S, Venugopal P, Rai K.
    Leukemia; 2005 Dec 15; 19(12):2147-52. PubMed ID: 16239912
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53.
    Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D.
    Haematologica; 2005 Oct 15; 90(10):1435-6. PubMed ID: 16219582
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T.
    Transfus Apher Sci; 2005 Feb 15; 32(1):33-44. PubMed ID: 15737872
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
    Karlsson C, Lundin J, Kimby E, Kennedy B, Moreton P, Hillmen P, Osterborg A.
    Br J Haematol; 2009 Jan 15; 144(1):78-85. PubMed ID: 19016731
    [Abstract] [Full Text] [Related]

  • 20. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
    Fiegl M, Falkner F, Steurer M, Zojer N, Hopfinger G, Haslbauer F, Winder G, Voskova D, Andel J, Lang A, Brychtova Y, Mayer J, Greil R, Gastl G, Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, Czech Leukemia Study Group for Life, CELL.
    Ann Hematol; 2011 Sep 15; 90(9):1083-91. PubMed ID: 21350830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.